205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.29%
Revenue growth above 1.5x ADI's 3.70%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
17.45%
Gross profit growth above 1.5x ADI's 4.80%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
99.20%
EBIT growth above 1.5x ADI's 12.76%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
99.20%
Operating income growth above 1.5x ADI's 12.76%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
269.42%
Net income growth above 1.5x ADI's 10.73%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
271.43%
EPS growth above 1.5x ADI's 10.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
257.14%
Diluted EPS growth above 1.5x ADI's 10.53%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.54%
Share reduction while ADI is at 0.48%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
3.44%
Diluted share count expanding well above ADI's 1.32%. Michael Burry would fear significant dilution to existing owners' stakes.
0.54%
Dividend growth of 0.54% while ADI is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
34.92%
OCF growth above 1.5x ADI's 7.90%. David Dodd would confirm a clear edge in underlying cash generation.
28.24%
FCF growth above 1.5x ADI's 2.96%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-3.87%
Negative 10Y revenue/share CAGR while ADI stands at 150.53%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
8.86%
5Y revenue/share CAGR under 50% of ADI's 46.25%. Michael Burry would suspect a significant competitive gap or product weakness.
-19.76%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
64.67%
10Y OCF/share CAGR under 50% of ADI's 410.23%. Michael Burry would worry about a persistent underperformance in cash creation.
-17.74%
Negative 5Y OCF/share CAGR while ADI is at 124.61%. Joel Greenblatt would question the firm’s operational model or cost structure.
4.61%
Positive 3Y OCF/share CAGR while ADI is negative. John Neff might see a big short-term edge in operational efficiency.
151.10%
Below 50% of ADI's 439.28%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
147.51%
Below 50% of ADI's 643.55%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-34.10%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
308.57%
10Y equity/share CAGR at 50-75% of ADI's 532.64%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
72.15%
5Y equity/share CAGR at 50-75% of ADI's 124.14%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-8.05%
Negative 3Y equity/share growth while ADI is at 49.05%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
31.93%
Dividend/share CAGR of 31.93% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-1.18%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
5.82%
3Y dividend/share CAGR of 5.82% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
5.69%
AR growth well above ADI's 6.74%. Michael Burry fears inflated revenue or higher default risk in the near future.
-0.50%
Inventory is declining while ADI stands at 1.18%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.09%
Asset growth 1.25-1.5x ADI's 2.20%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
5.01%
BV/share growth above 1.5x ADI's 3.03%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-4.68%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
10.38%
R&D growth drastically higher vs. ADI's 0.75%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-4.57%
We cut SG&A while ADI invests at 0.94%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.